To amend the Public Health Service Act to direct the Secretary of Health and Human Services to establish drug adherence guidelines, and for other purposes.

This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish drug adherence guidelines for covered drugs under Medicare so as to achieve an adherence rate of 90%. The CMS must incorporate artificial intelligence and machine-learning technologies and promote generics and biosimilars when developing the guidance.

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1142 Introduced in House (IH)]

<DOC>






119th CONGRESS
  1st Session
                                H. R. 1142

   To amend the Public Health Service Act to direct the Secretary of 
 Health and Human Services to establish drug adherence guidelines, and 
                          for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            February 7, 2025

Mr. Schweikert introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
   To amend the Public Health Service Act to direct the Secretary of 
 Health and Human Services to establish drug adherence guidelines, and 
                          for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. ESTABLISHMENT OF DRUG ADHERENCE GUIDELINES.

    Title XVII of the Public Health Service Act (42 U.S.C. 300u et 
seq.) is amended by inserting after section 1711 (42 U.S.C. 300u-16) 
the following:

``SEC. 1712. ESTABLISHMENT OF DRUG ADHERENCE GUIDELINES.

    ``(a) In General.--The Secretary shall establish drug adherence 
guidelines with the goal of achieving 90 percent adherence for all 
Medicare part B and D drugs.
    ``(b) Contents.--In establishing the guidelines under subsection 
(a), the Secretary shall--
            ``(1) incorporate artificial intelligence and machine 
        learning technologies; and
            ``(2) to the maximum extent practicable, promote the use of 
        generic and biosimilar drugs.
    ``(c) Definitions.--In this section:
            ``(1) Medicare part b drug.--The term `Medicare part B 
        drug' means a drug or biological product for which payment may 
        be made under part B of title XVIII of the Social Security Act 
        (42 U.S.C. 1395j et seq.).
            ``(2) Medicare part d drug.--The term `Medicare part D 
        drug' means a covered part D drug (as defined in section 1860D-
        2(e) of the Social Security Act (42 U.S.C. 1395w-102(e))).''.
                                 <all>